Equities
  • Price (EUR)105.00
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change+94.44%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Ligand Pharmaceuticals Inc had revenues fall -33.09% from 196.25m to 131.31m, though the company grew net income from a loss of 33.36m to a gain of 52.15m.
Gross margin93.52%
Net profit margin29.68%
Operating margin-12.68%
Return on assets5.25%
Return on equity6.00%
Return on investment5.37%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Ligand Pharmaceuticals Inc fell by 22.05m. However, the company earned 49.58m from its operations for a Cash Flow Margin of 37.75%. In addition the company used 11.68m on investing activities and also paid 59.95m in financing cash flows.
Cash flow per share4.37
Price/Cash flow per share27.27
Book value per share44.84
Tangible book value per share13.95
More ▼

Balance sheet in USDView more

Ligand Pharmaceuticals Inc uses little debt in its capital structure as supported by a debt to capital ratio of 0.00%.
Current ratio12.49
Quick ratio11.81
Total debt/total equity0.00003
Total debt/total capital0.00003
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)-12.71
EPS (TTM) vs
TTM 1 year ago
-6.51
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.